GlassScriptPhysician profile
Thomas W Ratliff
NPI 1639170665
$10,662.02
in general payments reported to CMS, 2019-2025
35 companies · $3,376 in 2025
The $3,376 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $1,680 · 2021: $177 · 2022: $1,870 · 2023: $1,289 · 2024: $2,166 · 2025: $3,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,117 · Food and Beverage: $2,619 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,116.67 |
| Food and Beverage | $2,619.38 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,378.21 | 2020-2025 | Imfinzi |
| Beigene USA, INC. | $1,723.03 | 2022-2024 | Tevimbra, Brukinsa |
| Glaxosmithkline, LLC. | $1,713.03 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $723.33 | 2025 | Vanflyta, Injectafer, Enhertu |
| Beigene, LTD. | $416.67 | 2023 | Brukinsa |
| Coherus Oncology, INC. | $312.62 | 2022-2025 | Loqtorzi |
| Gilead Sciences, INC. | $267.38 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $164.84 | 2019-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $151.12 | 2021-2023 | Imbruvica |
| Beone Medicines USA, INC. | $147.16 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $125.00 | 2023 | Monoferric |
| Mirati Therapeutics, INC. | $124.87 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $121.53 | 2023 | Libtayo |
| Pfizer INC. | $116.34 | 2019-2025 | |
| Amgen INC. | $109.35 | 2021-2024 | Kyprolis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $106.16 | 2023 | Clonoseq |
| Cti Biopharma Corp. | $100.53 | 2023 | Vonjo |
| Abbvie INC. | $97.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $95.53 | 2024-2025 | |
| Astellas Pharma US INC | $91.29 | 2025 | Vyloy |
| Genzyme Corporation | $88.54 | 2024 | |
| Janssen Biotech, INC. | $68.10 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Lilly USA, LLC | $67.74 | 2019-2025 | Verzenio, Jaypirca |
| Kyowa Kirin, INC. | $50.98 | 2024-2025 | Poteligeo |
| Takeda Pharmaceuticals U.S.A., INC. | $43.46 | 2024-2025 | Ninlaro, Fruzaqla |
| Caris Mpi, INC. | $42.22 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $41.58 | 2024-2025 | |
| Celgene Corporation | $30.88 | 2025 | Reblozyl |
| Legend Biotech USA INC. | $30.22 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $23.54 | 2025 | Xpovio |
| Sobi, INC | $21.30 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Eisai INC. | $18.09 | 2019 | |
| Merck Sharp & Dohme LLC | $16.38 | 2019 | |
| Seagen INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.